Get live statistics and analysis of Anne Wojcicki's profile on X / Twitter

To the 23andMe Community, I am incredibly excited and humbled to share with you that TTAM Research Institute (TTAM), a new non—profit medical research organization that I founded and lead, has completed the acquisition of 23andMe.   I formed TTAM and pursued the acquisition of 23andMe because of my strong belief that everyone should continue to have the ability to learn about and benefit from their DNA, and that a non-profit structure is the best way to solidify our values and commitments to our customers, the scientific community and the world at large. Since its founding in 2006, 23andMe has stood for something revolutionary: that individuals should have a right to understand themselves at the most fundamental level — through their DNA.   Through their DNA they can understand their health risks , prevent disease and be true partners in participating in research that shapes the future of health and medicine. Understanding the code of life - our DNA - is one of the most exciting scientific missions of our lifetime.  Through our DNA, we can learn about our ancestry origins, prevent potential health issues, and help develop treatments that could benefit all of us.   Humans are 99.5% genetically identical, and we have DNA in common with everything alive today.  The pursuit to understand DNA will benefit all of us and all of life. That belief built one of the world’s most diverse and engaged genetic research communities. More than 15 million people have joined this journey, and over 80% have chosen to participate in research, contributing to over 275 peer-reviewed publications in cancer, cardiovascular disease, neurological disorders, and more.   These discoveries did not just stay academic - those discoveries were also translated into new genetic reports  for customers that helped them continue to learn about their own DNA.    Thank you to the 23andMe community that participated in research and contributed to discoveries that have had a meaningful impact for the world. I want to end on a personal note.   Over the last few years I unfortunately lost my father, my nephew and my sister.   These tragedies have sharpened my focus on what is most important to me and how I want to spend my time.   My passion is 23andMe.  The opportunity to give back to society with our research and help everyone benefit from learning about their genome with a healthier life, is a personal mission where I am dedicating my resources and my time.    We all have a disease or health condition that we care about .  By coming together as a single community, we are stronger and more powerful to make discoveries and to ultimately make a difference.   The future of healthcare belongs to all of us and it’s in our power to make a difference. I am honored to be back with 23andMe and look forward to sharing more with you in the weeks and years to come. With gratitude, Anne

The 23andMe Special Committee released news today indicating their plan to take the company through the Chapter 11 process.   While I am disappointed that we have come to this conclusion and my bid was rejected, I am supportive of the company and I intend to be a bidder.   I have resigned as CEO of the company so I can be in the best position to pursue the company as an independent bidder.  Nineteen years ago, when I co-founded 23andMe, the direct to consumer industry did not exist and most people had no idea why they would ever want to see their genome.   So much has changed.   There is now a thriving direct to consumer industry and over 15 million people are now 23andMe customers.   These customers are continuing to learn about their family relationships and how to optimize their health thanks to the incredible team of individuals at 23andMe who innovate and help customers gain insights from their genetic information. What made so many of our innovations possible were the 85% of our customers who opted in to research.  Thanks to them they have empowered an incredible platform for discovery.  You enabled our pursuit into novel drug discovery and our 50 programs with GSK.   In addition, over 250 publications have come out because of you and we have meaningfully impacted the research world.   Thank you. We have had many successes but I equally take accountability for the challenges we have today. There is no doubt that the challenges faced by 23andMe through an evolving business model have been real, but my belief in the company and its future is unwavering.  Consumers are rising up and asking for more control over their health and want greater knowledge about how to be healthy and why they may have health issues. We fought for consumers to have direct access to their information and for them to have choice and transparency with respect to their personal data.   As I think about the future, I will continue to tirelessly advocate for customers to have choice and transparency with respect to their personal data, regardless of platform. Since 2006, we have built an incredible consumer brand with one of the world's largest and most diverse genetic communities. Our foundation was the trust and respect of our customers, and they were always the guiding light on how we made decisions. If I am fortunate enough to secure the company’s assets through the restructuring process, I remain committed to our long-term vision of being a global leader in genetics and establishing genetics as a fundamental part of healthcare ecosystems worldwide.

1/ Last year, I lost my sister Susan to lung cancer. Lung cancer in people who never smoked is the 5th leading cause of cancer globally. It kills more people than breast, colon, and prostate cancer combined. Today at 23andMe, we’re announcing steps to accelerate breakthroughs:

The information below is wrong because you are confusing raw data with an FDA cleared report. After a year of being relatively silent, I am eager to make it clear what 23andMe stands for and how absolutely wrong this comment below is. 23andMe has been and always will be focused on providing individuals with affordable, high quality information. In a world of increasing confusion about what is real health information, we are passionately committed to always doing right by our members and being their advocate for accurate, real health information. 23andMe’s FDA-reviewed BRCA1/BRCA2 “Selected Variants” test shows greater than 99% analytic accuracy (concordance) and greater than 99% reproducibility for the specific variants it reports. This applies only to a defined panel of 44 variants, not to all possible BRCA mutations. The FDA submissions report >99% concordance with Sanger sequencing for each BRCA1/2 variant that 23andMe tests, meaning the lab calls for those variants almost always match a gold-standard sequencing result. The same studies show >99% reproducibility and repeatability across runs and laboratory conditions for those variants. These performance metrics met FDA requirements in the original De Novo authorization (3 variants) and the later 510(k) clearance that expanded the panel to 44 variants. The study you reference compared raw SNP data to NGS. The fact that ultra-rare variants were mostly “false-positives” is not surprising. We don't report ultra-rare variants to our members. We report variants that are common enough to identify accurately by genotyping and that meet our very rigorous validation standards as mentioned above. Anyone can access their raw data and some people choose to upload their raw results elsewhere to get an “interpretation”. We explicitly caution against doing that because we cannot vouch for any variant on the array that hasn't undergone validation. This is what we say in our customer care page on the topic: “The raw data provided by 23andMe has undergone a general quality review, however, only a subset of markers have been individually validated for accuracy. The data from 23andMe’s Browse Raw Data feature is suitable only for informational use and not for medical, diagnostic, or other use. We advise that you consult with a healthcare professional before making any major lifestyle changes.”

In my 52 years I have never had twins in my eggs! Anyone else see this before?

The 23andMe Special Committee released news today indicating their plan to take the company through the Chapter 11 process.   While I am disappointed that we have come to this conclusion and my bid was rejected, I am supportive of the company and I intend to be a bidder.   I have resigned as CEO of the company so I can be in the best position to pursue the company as an independent bidder.  Nineteen years ago, when I co-founded 23andMe, the direct to consumer industry did not exist and most people had no idea why they would ever want to see their genome.   So much has changed.   There is now a thriving direct to consumer industry and over 15 million people are now 23andMe customers.   These customers are continuing to learn about their family relationships and how to optimize their health thanks to the incredible team of individuals at 23andMe who innovate and help customers gain insights from their genetic information. What made so many of our innovations possible were the 85% of our customers who opted in to research.  Thanks to them they have empowered an incredible platform for discovery.  You enabled our pursuit into novel drug discovery and our 50 programs with GSK.   In addition, over 250 publications have come out because of you and we have meaningfully impacted the research world.   Thank you. We have had many successes but I equally take accountability for the challenges we have today. There is no doubt that the challenges faced by 23andMe through an evolving business model have been real, but my belief in the company and its future is unwavering.  Consumers are rising up and asking for more control over their health and want greater knowledge about how to be healthy and why they may have health issues. We fought for consumers to have direct access to their information and for them to have choice and transparency with respect to their personal data.   As I think about the future, I will continue to tirelessly advocate for customers to have choice and transparency with respect to their personal data, regardless of platform. Since 2006, we have built an incredible consumer brand with one of the world's largest and most diverse genetic communities. Our foundation was the trust and respect of our customers, and they were always the guiding light on how we made decisions. If I am fortunate enough to secure the company’s assets through the restructuring process, I remain committed to our long-term vision of being a global leader in genetics and establishing genetics as a fundamental part of healthcare ecosystems worldwide.

To the 23andMe Community, I am incredibly excited and humbled to share with you that TTAM Research Institute (TTAM), a new non—profit medical research organization that I founded and lead, has completed the acquisition of 23andMe.   I formed TTAM and pursued the acquisition of 23andMe because of my strong belief that everyone should continue to have the ability to learn about and benefit from their DNA, and that a non-profit structure is the best way to solidify our values and commitments to our customers, the scientific community and the world at large. Since its founding in 2006, 23andMe has stood for something revolutionary: that individuals should have a right to understand themselves at the most fundamental level — through their DNA.   Through their DNA they can understand their health risks , prevent disease and be true partners in participating in research that shapes the future of health and medicine. Understanding the code of life - our DNA - is one of the most exciting scientific missions of our lifetime.  Through our DNA, we can learn about our ancestry origins, prevent potential health issues, and help develop treatments that could benefit all of us.   Humans are 99.5% genetically identical, and we have DNA in common with everything alive today.  The pursuit to understand DNA will benefit all of us and all of life. That belief built one of the world’s most diverse and engaged genetic research communities. More than 15 million people have joined this journey, and over 80% have chosen to participate in research, contributing to over 275 peer-reviewed publications in cancer, cardiovascular disease, neurological disorders, and more.   These discoveries did not just stay academic - those discoveries were also translated into new genetic reports  for customers that helped them continue to learn about their own DNA.    Thank you to the 23andMe community that participated in research and contributed to discoveries that have had a meaningful impact for the world. I want to end on a personal note.   Over the last few years I unfortunately lost my father, my nephew and my sister.   These tragedies have sharpened my focus on what is most important to me and how I want to spend my time.   My passion is 23andMe.  The opportunity to give back to society with our research and help everyone benefit from learning about their genome with a healthier life, is a personal mission where I am dedicating my resources and my time.    We all have a disease or health condition that we care about .  By coming together as a single community, we are stronger and more powerful to make discoveries and to ultimately make a difference.   The future of healthcare belongs to all of us and it’s in our power to make a difference. I am honored to be back with 23andMe and look forward to sharing more with you in the weeks and years to come. With gratitude, Anne

1/ Last year, I lost my sister Susan to lung cancer. Lung cancer in people who never smoked is the 5th leading cause of cancer globally. It kills more people than breast, colon, and prostate cancer combined. Today at 23andMe, we’re announcing steps to accelerate breakthroughs:

In my 52 years I have never had twins in my eggs! Anyone else see this before?

The information below is wrong because you are confusing raw data with an FDA cleared report. After a year of being relatively silent, I am eager to make it clear what 23andMe stands for and how absolutely wrong this comment below is. 23andMe has been and always will be focused on providing individuals with affordable, high quality information. In a world of increasing confusion about what is real health information, we are passionately committed to always doing right by our members and being their advocate for accurate, real health information. 23andMe’s FDA-reviewed BRCA1/BRCA2 “Selected Variants” test shows greater than 99% analytic accuracy (concordance) and greater than 99% reproducibility for the specific variants it reports. This applies only to a defined panel of 44 variants, not to all possible BRCA mutations. The FDA submissions report >99% concordance with Sanger sequencing for each BRCA1/2 variant that 23andMe tests, meaning the lab calls for those variants almost always match a gold-standard sequencing result. The same studies show >99% reproducibility and repeatability across runs and laboratory conditions for those variants. These performance metrics met FDA requirements in the original De Novo authorization (3 variants) and the later 510(k) clearance that expanded the panel to 44 variants. The study you reference compared raw SNP data to NGS. The fact that ultra-rare variants were mostly “false-positives” is not surprising. We don't report ultra-rare variants to our members. We report variants that are common enough to identify accurately by genotyping and that meet our very rigorous validation standards as mentioned above. Anyone can access their raw data and some people choose to upload their raw results elsewhere to get an “interpretation”. We explicitly caution against doing that because we cannot vouch for any variant on the array that hasn't undergone validation. This is what we say in our customer care page on the topic: “The raw data provided by 23andMe has undergone a general quality review, however, only a subset of markers have been individually validated for accuracy. The data from 23andMe’s Browse Raw Data feature is suitable only for informational use and not for medical, diagnostic, or other use. We advise that you consult with a healthcare professional before making any major lifestyle changes.”

Even fruits and vegetables find surprising new relationships in their family tree!

Jasmine and her grandmother were such a pleasure to meet tonight! Can’t wait to see what you do next Jasmine!